AG 13958

Drug Profile

AG 13958

Alternative Names: AG-013,958; AG-13958

Latest Information Update: 11 Mar 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Eye disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 11 Mar 2008 Discontinued - Phase-I/II for Age-related macular degeneration in Australia (Ophthalmic)
  • 11 Mar 2008 Discontinued - Phase-I/II for Age-related macular degeneration in United Kingdom (Ophthalmic)
  • 11 Mar 2008 Discontinued - Phase-I/II for Age-related macular degeneration in Netherlands (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top